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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
We will assess the effect of the topical application of oils versus that of other topical oils, emollients, placebo or no treatment:
1. in the prevention of dry skin in term (≥ 37 weeks of gestation) newborn infants; and
2. in the treatment of dry skin in term (≥ 37 weeks of gestation) newborn infants.
B A C K G R O U N D
Description of the condition
Dry skin is a common occurrence in the first few months of an
infant’s life (Saijo 1991). Dry skin has been defined as “a cuta-
neous reaction pattern reflecting abnormal desquamation of di-
verse etiologies” (Madison 2003). In normal skin, corneocytes are
shed from the skin in small enough quantities that they are not
visible to the naked eye; however, in dry skin, the skin appearance
becomes rough and flaky if this normal process is disturbed in any
way. In an infant, this is a normal process of adaptation to life
outside the uterus.
Atopic eczema (synonym atopic dermatitis) is an inflammatory
skin condition characterised by dry and scaly skin, redness, blister-
ing and itching. It affects up to 30% of children aged 2 to 15 years
in the UK (Gupta 2004). Affected children are also predisposed to
allergic asthma and allergic rhinitis (Gustafsson 2000). It is sug-
gested that approximately 60% of sufferers develop atopic eczema
in their first year of life (Bieber 2008). Prevalence has increased to
this current level from approximately 5% of children in the 1940s
(Taylor 1984). During that time the genetic structure of skin has
not changed; however, the way that we care for an infant’s skin has
changed, with an increase in use of soaps, other harsh detergents
and oils (Cork 2009; Danby 2011a).
Infant skin is physiologically different to adult skin. The stratum
corneum is 30% thinner and the epidermis is 20% thinner in in-
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fants than in adults (Stamatas 2010). This difference in skin struc-
ture results in increases in permeability and dryness in infant skin.
Infant skin is also more vulnerable to the use of topical treatments,
as the ratio of infant body surface to body weight is higher than
that for adults; hence, the risk that such therapies will be absorbed
through the skin is greater in infants than in adults (Nikolovski
2008). As the infant skin barrier continues to develop during the
first year of life (Stamatas 2011), infants are vulnerable to this risk
throughout this period. Infant skin is prone to an increased rate of
transepidermal water loss (TEWL) and reduced stratum corneum
hydration because it contains fewer lipids and natural moisturising
factors, and less melanin than adult skin (Chiou 2004; Nakagawa
2004). Infants may also experience a weakening of the skin bar-
rier due to their elevated skin surface pH. High skin surface pH
(low acidity) results in increased activity of proteases, which break-
down corneodesmosomes (the supportive component of the stra-
tum corneum), and hinders the activity of enzymes that are re-
quired for lipid processing (Hachem 2003; Cork 2009).
These differences in both structure and function between infant
and adult skin suggest that infant skin is more vulnerable to envi-
ronmental factors, including infant skin care products. The use of
some topical oils and emollients on infant skin may therefore con-
tribute to the development of adverse skin conditions, including
atopic eczema, whereas other topical oils may have a positive effect
and prevent the development of this condition (Danby 2011a;
Danby 2011b; Danby 2013).
Description of the intervention
Parents want to use skin products that make their infant look and
smell nice (Lavender 2009; Furber 2012). The application of oil is
commonly recommended by health professionals to new parents
for use on their newborn infant’s skin (Lavender 2009; Cooke
2011), in order to prevent or treat dryness or for massage. The use
of emollients is not commonly recommended; however, parents
have the choice of a diverse range of emollient infant skin care
products from numerousmanufacturers. In aUKnational survey (
Cooke 2011), 52% ofmaternity and neonatal units recommended
the use of oil; 82% of these units recommended olive oil to parents
for use on their infant’s skin and 20% recommended sunflower oil.
Health professionals, such as midwives and health visitors, believe
these oils to be natural and, therefore, not harmful to infant skin
(Lavender 2009). Infant skin conditions can cause parental anxiety
(Adalat 2007). Parents will often adhere to advice given to them
by health professionals with regard to the care of a newborn infant
(Lavender 2009).
How the intervention might work
Some oils have been shown to have a positive effect on skin bar-
rier function (Darmstadt 2004; Darmstadt 2008; Danby 2013),
whereas others may impair this function (Naik 1995; Darmstadt
2002a; Jiang 2003; Danby 2013). Research has shown that olive
oil of a certain composition (i.e. a high ratio of oleic acid to
linoleic acid) may adversely affect skin barrier function in mice
(Darmstadt 2002a; Jiang 2003) and adults (Naik 1995; Danby
2013). This composition of oil disrupts the lipid structure of the
stratum corneum, and is a potential risk factor in the development
or exacerbation of atopic eczema. Optimal sunflower oil (i.e. a
high ratio of linoleic acid to oleic acid) has been shown in the
same population to promote skin barrier repair (Darmstadt 2004;
Darmstadt 2008; Danby 2013).
The use of emollients or moisturisers is common in skin care reg-
imens. They act by preventing water loss or by actively hydrating
the skin (Elson 2011). The main reason to use emollients in skin
care is to protect the integrity of the skin barrier. For healthy term
infants, this is not clinically necessary; however, those infants at
risk (such as those with a family history of atopic eczema) may
benefit from the regular use of emollients (Frieden 2011). An oil
is also an emollient that helps to prevent water loss and lubricates
the skin.
Why it is important to do this review
Societal interest in ‘natural’ products is high (Allemann 2009), es-
pecially in parents of newborn infants (Cottingham 2007). There
is a readiness among parents to use oil for infant skin care, and a
readiness among maternity professionals to recommend it. There
is a misconception that because a product is ‘natural’ it must be
‘safe’ (Lavender 2009; Bedwell 2012). Oils have been used in
the cosmetic, pharmaceutical and perfumery industries for many
years. Although oils are governed by guidelines for the testing
and research of cosmetics (Council of the European Communities
1976), these are not as rigorous as those governing the use of
medicines in humans (Department of Health 2004). This means
that oils have been used as medicinal and homeopathic remedies
for many years without any collection and analysis of toxicological
data. The infant skin surface area in relation to body weight is
high and absorption is relative to the surface area exposed (Rutter
1987). Topical applications may cause irritation, damage or sys-
temic effects through absorption of the oil in to the body.
Infection is one of the leading causes of neonatal morbidity and
mortality in low-resource countries (Darmstadt 2002a). The vul-
nerability of infant skin and the use of oils that may be harmful,
combined with poor hygiene conditions, have the potential for
increased hazards of infection. Nosocomial sepsis is more com-
mon in preterm infants, in whom the stratum corneum is not
fully mature (Conner 2009) and the skin does not have the pro-
tective benefit of vernix (Yoshio 2003), than in term infants. Sev-
eral studies (Darmstadt 2002b; Darmstadt 2004; Edwards 2004;
Darmstadt 2005; Darmstadt 2008; Kiechl-Kohlendorfer 2008)
and a Cochrane systematic review (Conner 2009) have considered
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topical applications for preterm infants, but no review has consid-
ered the evidence in term infants.
We know that 45% and 60% of atopic eczema cases occur in the
first six months and year of life, respectively (Bieber 2008). This
period of time is when midwives, maternity workers and other
infant health professionals have the most influence with parents.
Health professionals find it difficult to give evidence-based advice
to new parents, as there is insufficient evidence to guide practice.
It is therefore important to systematically review what evidence
there is, to provide a high-quality basis for clinical practice and in-
formed decision-making. Some oils are potentially harmful; how-
ever, others may provide some benefit. Given the rise in the preva-
lence of atopic eczema, it is timely to evaluate current evidence
in order to provide the most appropriate advice for parents and
health professionals.
This review will assess the effects of topical oils and emollients
in the prevention or treatment of dry skin compared to the use
of alternative oils and emollients or no treatment in term infants.
The reviewwill complement the body of work held in theCochrane
Database of Systematic Reviews, which includes reviews such as
those investigating the prevention of infection in preterm infants
(Conner 2009; Seliem 2009) and the prevention of napkin der-
matitis in infants (Davies 2009).
A systematic review will provide:
1. an evidence base to inform parents and health professionals
in their practice with healthy term newborn infants, rather than
remain in confusion regarding which oil or emollient, if any, to
recommend or use; and
2. highlight any area that requires further investigation.
O B J E C T I V E S
We will assess the effect of the topical application of oils versus
that of other topical oils, emollients, placebo or no treatment:
1. in the prevention of dry skin in term (≥ 37 weeks of gestation)
newborn infants; and
2. in the treatment of dry skin in term (≥ 37 weeks of gestation)
newborn infants.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised and quasirandomised controlled trials (including
cluster and parallel trials, and trials in which the infant serves as
his/her own control) comparing the topical application of oils with
the topical application of other oils, emollients or placebo, or with
no treatment will be considered.
Types of participants
We will include newborn term (≥ 37 weeks of gestation) infants
receiving the application of topical oils or emollients:
1. for the prevention of dry skin within the first 28 days following
birth; or
2. for the treatment of dry skin within the first 28 days following
birth.
There is no upper gestational age limit for eligibility.
For the purposes of this review, dry skin will be diagnosed using a
validated skin assessment scoring tool (Lane 1993; Lund 2001) or
skin surface hydration measurement tool (e.g. a Corneometer®),
or by clinical observation by amidwifery, neonatal or dermatology
health professional.
We will include infants with normal skin and infants with a family
history of atopic eczema. Normal infant skin variations, such as
erythema neonatorum, erythema toxicum or milia, will not be
considered as skin disorders, and will therefore be included. A
family history of atopic eczema will be defined as “at least one of
mother, father or sibling who has a medical diagnosis of atopic
eczema/atopic dermatitis and who is treated with topical steroidal
treatment”. Infants diagnosed with an impairment of epidermal
integrity, abnormal epidermis or dermis, such as collodion infant
or congenital ichthyosis, will be excluded.
Wewill exclude newborn preterm (< 37weeks of gestation at birth)
infants, as this population has been included in another review
(Seliem 2009).
Types of interventions
All of the stated interventions will be considered separately for
both the prevention and treatment of dry skin.
Intervention
1. Application of topical oils, which may include any type of
oil (such as olive oil, sunflower oil, coconut oil, grape seed oil,
borage oil, evening primrose oil, other vegetable oil) compared
with placebo or no topical applications
2. Application of topical emollients compared with placebo or
no topical applications
Other Interventions
1. Intervention oil versus another topical oil
2. Intervention emollient versus another topical application
(such as emollient, gel, cream, lotion or powder)
3. Intervention oil versus another topical application (such as
emollient, gel, cream, lotion or powder)
It is expected that other products, such as soaps or bathing prod-
ucts, may be used on the infants in the trials. It is also expected
that there will be variations in the dose, area, frequency and du-
ration of application of the interventions. If there are substantial
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differences across trials, data will not be pooled but reported sep-
arately. Where combinations of topical applications are applied,
data from a combination of treatments will not be pooled with
data for single treatments.
Types of outcome measures
Where appropriate, data will be pooled or, if necessary (and ap-
propriate), dichotomised. Outcomes will be analysed at baseline
and at further time points up to 28 days (e.g. 7, 14, 28 days).
Primary outcomes
1. Change in skin surface hydration, measured using a
Corneometer® or similar validated tool, within 28 days
following birth
2. Change in TEWL, measured using an Aquaflux,
Tewameter® or similar validated tool, within 28 days following
birth
Secondary outcomes
1. Change in skin assessment scores, measured using the
Neonatal Skin Condition Score (Lund 2001) or the Skin
Condition Grading Scale (Lane 1993) within 28 days following
birth.
2. Systemic or cutaneous infection, confirmed by diagnosis
more than 48 hours after birth, as determined by culture of
swabs from a normally sterile skin site
3. Change in skin surface pH, measured using a Skin-pH-
meter or similar validated tool, within 28 days following birth
4. Atopic eczema, confirmed by clinical diagnosis by a
dermatologist
5. Clinical observations of adverse skin conditions (visible
signs of skin barrier dysfunction such as erythema/rash),
measured using a Mexameter® or similar validated tool, or
documented clinical examination, within 28 days following birth
6. Maternal satisfaction with regard to using oils for infant
skin care or condition of infant’s skin, as measured by
questionnaire response
7. Other skin-related outcomes not identified a priori by the
reviewers but reported by trial authors
Search methods for identification of studies
We will use the standard search strategy of the Cochrane Neonatal
Review Group.
Electronic searches
We will identify randomised controlled trials from the Cochrane
Central Register of Controlled Trials (CENTRAL, latest issue of
The Cochrane Library).We will identify all other trials fromMED-
LINE (1966 to current), EMBASE (1980 to current), CINAHL
(1982 to current), Dissertation Abstracts (1980 to current) and
SIGLE (2000 to current). We will list the full search strategies
for these databases in the review. We will identify ongoing clinical
trials through searching www.clinicaltrials.gov.
We will not apply any language restrictions. We will use the
following text words or medical subject heading terms: infant,
neonate, newborn, baby, plant oils, oils, emollients, oleic acid,
oleic, linoleic, skin barrier function, epidermal barrier function,
skin scores, atopic march, dry skin, atopic eczema, atopic dermati-
tis.
Searching other resources
We will search for further studies in the reference lists of all identi-
fied articles. We will not apply language, start date or geographical
restrictions. We will approach the clinical research departments
of all major pharmaceutical and cosmetic companies to request
access to their unpublished research (see Appendix 1). We will
contact subject experts to identify ongoing, unpublished research.
Abstracts presented at the annual meetings of the Society for Pedi-
atric Research, the American Pediatric Society, and the European
Society for Paediatric Research, and published in the journal Pe-
diatric Research, will be handsearched. We will include trials pre-
sented in abstract form only if sufficient data are available from
the abstract, or from contact with the author.
Data collection and analysis
We will use the standard methods of the Cochrane Neonatal Re-
view Group.
Selection of studies
Two review authors (AC, TL) will independently assess for inclu-
sion all the potential studies we identify as a result of the search
strategy. We will resolve any disagreement through discussion or,
if required, we will consult a third review author (SV or MC).
Data extraction and management
Wewill design a form for the extractionof data. For eligible studies,
at least two review authors (AC, TL) will extract data using the
agreed form. We will resolve discrepancies through discussion or,
if required, we will consult a third review author (SV/MC). We
will enter data into Review Manager (RevMan 2011) and check
them for accuracy.
We will attempt to contact authors of the original reports to pro-
vide further details when information regarding the above is un-
clear.
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Assessment of risk of bias in included studies
Two review authors (AC, TL) will independently assess the risk
of bias in each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreement by discussion or by involving a
third review author (SV/MC).
(1) Sequence generation (checking for possible selection bias)
For each included study we will describe the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
We will assess the method as:
• adequate (any truly random process, e.g. random number
table; computer random number generator);
• inadequate (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number);
• unclear.
(2) Allocation concealment (checking for possible selection
bias)
For each included study we will describe the method used to
conceal the allocation sequence in sufficient detail and determine
whether intervention allocation could have been foreseen in ad-
vance of or during recruitment, or changed after assignment.
We will assess the methods as:
• adequate (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• inadequate (open random allocation; unsealed or non-
opaque envelopes; alternation; date of birth);
• unclear.
(3) Blinding (checking for possible performance bias)
We will describe for each included study the methods used, if
any, to blind outcome assessors, participants and personnel from
knowledge of which intervention a participant received. We will
judge studies at low risk of bias if they were blinded, or if we judge
that the lack of blinding could not have affected the results. We
will assess the methods for blinding separately under the headings:
participants, personnel and outcomes.
We will assess the methods as:
• adequate;
• inadequate;
• unclear.
(4) Incomplete outcome date (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We will describe for each included study, and for each outcome
or class of outcomes, the completeness of data, including attrition
and exclusions from the analysis. We will state whether attrition
and exclusions were reported, the numbers included in the analysis
at each stage (compared with the total numbers of randomised
participants), reasons for attrition or exclusion, where reported,
and whether missing data were balanced across groups or were
related to outcomes. Where sufficient information is reported, or
can be supplied by the trial authors, we will re-include missing
data in the analyses that we undertake.
We will assess the methods as:
• adequate (where fewer than 20% of the data are missing);
• inadequate (where more than 20% of the data are missing);
• unclear.
(5) Selective reporting bias
We will describe for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• adequate (where it is clear that all of the study’s prespecified
outcomes and all expected outcomes of interest to the review
have been reported);
• inadequate (where not all of the study’s prespecified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear.
(6) Other sources of bias
We will describe for each included study any important concerns
we have about other possible sources of bias.
We will assess whether each study was free of other problems that
could put it at risk of bias as:
• yes;
• no;
• unclear.
(7) Overall risk of bias
We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
With reference to (1) to (6) above, we will assess the likely magni-
tude and direction of the bias, and whether we consider it is likely
to impact on the findings. We will explore the impact of the level
of bias through sensitivity analyses (see ‘Sensitivity analysis’).
Measures of treatment effect
Dichotomous data
We will present results as summary risk ratios and risk differences
with 95%confidence intervals for dichotomous data. If statistically
significant, we will present the number needed to treat for an
additional beneficial or harmful outcome (NNTB/NNTH).
Continuous data
We will use the weighted mean difference for continuous data
if outcomes are measured in the same way in all trials. We will
use the standardised mean difference to combine data from trials
that measure the same outcome using different methods. We will
present these data with 95% confidence intervals.
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Unit of analysis issues
Randomised trials where participant serves as own control
We will include these trials along with individually randomised
trials. We will consider it reasonable to combine the results from
both types of study if there is little heterogeneity between the study
designs.
Cluster randomised trials
Wewill include cluster randomised trials in the analyses along with
individually randomised trials. We will adjust their sample sizes
by means of the methods described in the Cochrane Handbook for
Systematic Reviews of Interventions, using an estimate of the intra-
cluster correlation coefficient (ICC) derived from the trial (if pos-
sible), from a similar trial or from a study of a similar population
(Higgins 2011). If we use ICCs from other sources, we will report
this and conduct sensitivity analyses to investigate the effect of
variation in the ICC. If we identify both cluster randomised trials
and individually randomised trials, we plan to synthesise the rel-
evant information. We will consider it reasonable to combine the
results from both if there is little heterogeneity between the study
designs and an interaction between the effect of intervention and
the choice of randomisation unit is considered to be unlikely. We
will seek statistical advice for this part of the analysis.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Dealing with missing data
For included studies, wewill note levels of attrition.Wewill explore
the impact of including studies with high levels of missing data in
the overall assessment of treatment effect using sensitivity analyses.
For all outcomes, we will carry out analyses, as far as possible, on
an intention-to-treat basis (i.e. we will attempt to include all par-
ticipants randomised to each group in the analyses, and analyse all
participants in the group to which they were allocated, regardless
of whether or not they received the allocated intervention). The
denominator for each outcome in each trial will be the number
randomised minus any participants whose outcomes are known
to be missing.
Assessment of heterogeneity
We will assess statistical heterogeneity in each meta-analysis using
the I2 statistic. We will identify heterogeneity using the following
categories: less than 25%, no heterogeneity; 25% to 40%, low
heterogeneity; 50% to 74%, moderate heterogeneity; and 75%
or greater, high heterogeneity. We will explore substantial hetero-
geneity (≥ 75%), if identified, using subgroup analyses.
Assessment of reporting biases
Where we suspect reporting bias (see ‘Selective reporting bias’),
we will attempt to contact study authors asking them to provide
missing outcome data. Where this is not possible, and the missing
data are thought to introduce serious bias, we will explore the
impact of including such studies in the overall assessment of results
using sensitivity analyses.
We will create funnel plots using Review Manager version 5.2 (
RevMan 2011) and assess the presence of publication bias by visual
inspection of the plots for funnel plot asymmetry. Unfortunately,
where the effect measure for dichotomous outcomes is the relative
risk (or risk ratio), as is the case for potentially two of the outcomes
in this review (skin assessment scores and maternal satisfaction),
there is limited evidence to underpin the statistical assessment of
funnel plot asymmetry (Higgins 2011). Therefore, we will limit
our assessment of funnel plot asymmetry to a visual inspection
only.
Data synthesis
Statistical analyses will be performed using the standard methods
of the Cochrane Neonatal Review Group. Review Manager ver-
sion 5.2 (RevMan 2011) will be used for meta-analyses. We will
use fixed-effect meta-analyses for combining data where it is rea-
sonable to assume that studies are estimating the same underlying
treatment effect (i.e. where trials are examining the same inter-
vention, and the trials’ populations and methods are judged to be
sufficiently similar). If there is clinical heterogeneity sufficient to
expect that the underlying treatment effects differ between trials,
or if we detect substantial statistical heterogeneity (see ‘Assessment
of heterogeneity’), we will attempt to explain the heterogeneity
identified in the fixed-effect model based on differences in clinical,
quality or other characteristics between studies.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses based on:
1. setting: high-income countries (gross national income
(GNI) per capita $4036 or more) versus low-income countries
(GNI per capita $4035 or less (World Bank 2012));
2. ethnicity: white versus black and minority ethnic;
3. family history of atopic eczema (“at least one of father,
mother, or sibling, who has a medical diagnosis of atopic eczema
and who has had topical steroid treatment”) versus no family
history of atopic eczema.
For fixed-effect meta-analyses, we will conduct planned subgroup
analyses classifying whole trials by interaction tests as described by
Deeks 2001.
Sensitivity analysis
We will perform sensitivity analyses based on trial quality, sepa-
rating high-quality trials from trials of lower quality. We will de-
fine high quality, for the purposes of this sensitivity analysis, as
a trial having adequate allocation concealment and a ‘reasonably
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expected loss to follow up’ (classified as less than 10%). We will
restrict sensitivity analyses to primary outcomes.
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Kao Corporation
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